Eupraxia Pharmaceuticals, Inc. (TSE:EPRX) has released an update.
Eupraxia Pharmaceuticals Inc., a clinical-stage biotech company focused on developing extended-release treatments, has announced the initiation of trading on the Nasdaq under the ticker symbol ‘EPRX’. The company, known for its proprietary Diffusphere™ technology, also continues to trade on the Toronto Stock Exchange. Eupraxia has recently seen success with its lead product candidate in a Phase 2b clinical trial and is expanding its portfolio into other therapeutic areas.
For further insights into TSE:EPRX stock, check out TipRanks’ Stock Analysis page.
